NO941477L - - Google Patents

Info

Publication number
NO941477L
NO941477L NO941477A NO941477A NO941477L NO 941477 L NO941477 L NO 941477L NO 941477 A NO941477 A NO 941477A NO 941477 A NO941477 A NO 941477A NO 941477 L NO941477 L NO 941477L
Authority
NO
Norway
Application number
NO941477A
Other languages
Norwegian (no)
Other versions
NO941477D0 (no
NO300461B1 (no
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of NO941477D0 publication Critical patent/NO941477D0/no
Publication of NO941477L publication Critical patent/NO941477L/no
Publication of NO300461B1 publication Critical patent/NO300461B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO941477A 1991-10-24 1994-04-22 2,6-Disubstituerte purinderivater NO300461B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK9100324 1991-10-24
PCT/DK1992/000307 WO1993008206A1 (fr) 1991-10-24 1992-10-21 Nouveaux derives de purine 2,6-disubstitues

Publications (3)

Publication Number Publication Date
NO941477D0 NO941477D0 (no) 1994-04-22
NO941477L true NO941477L (fr) 1994-06-23
NO300461B1 NO300461B1 (no) 1997-06-02

Family

ID=8153695

Family Applications (1)

Application Number Title Priority Date Filing Date
NO941477A NO300461B1 (no) 1991-10-24 1994-04-22 2,6-Disubstituerte purinderivater

Country Status (11)

Country Link
US (2) US5432164A (fr)
EP (1) EP0609375A1 (fr)
JP (1) JPH07500586A (fr)
AU (1) AU657374B2 (fr)
CA (1) CA2121844A1 (fr)
FI (1) FI941876A (fr)
IL (1) IL103513A (fr)
NO (1) NO300461B1 (fr)
NZ (1) NZ244875A (fr)
WO (1) WO1993008206A1 (fr)
ZA (1) ZA928222B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5432164A (en) * 1991-10-24 1995-07-11 Novo Nordisk A/S C2,N6 -disubstituted adenosine derivatives
US5589467A (en) * 1993-09-17 1996-12-31 Novo Nordisk A/S 2,5',N6-trisubstituted adenosine derivatives
EP0704215A3 (fr) * 1994-06-02 1998-04-01 Takeda Chemical Industries, Ltd. Inhibiteur de l'aumentation de la perméabilité vasculaire
AU2022597A (en) * 1996-03-13 1997-10-01 Novo Nordisk A/S A method of treating disorders related to cytokines in mammals
WO1997033590A1 (fr) * 1996-03-13 1997-09-18 Novo Nordisk A/S Procede de traitement d'affections associees aux cytokines chez les mammiferes
US5789416B1 (en) * 1996-08-27 1999-10-05 Cv Therapeutics Inc N6 mono heterocyclic substituted adenosine derivatives
AU4377397A (en) * 1996-10-14 1998-05-11 Novo Nordisk A/S Novel therapeutically active adenosine derivatives
US6110902A (en) * 1997-06-23 2000-08-29 Moehler; Hanns Method for the inhibition of neuronal activity leading to a focal epileptic seizure by local delivery of adenosine
US6175004B1 (en) * 1998-09-01 2001-01-16 Isis Pharmaceuticals, Inc. Process for the synthesis of oligonucleotides incorporating 2-aminoadenosine
US6576619B2 (en) 1999-05-24 2003-06-10 Cv Therapeutics, Inc. Orally active A1 adenosine receptor agonists
US6294522B1 (en) * 1999-12-03 2001-09-25 Cv Therapeutics, Inc. N6 heterocyclic 8-modified adenosine derivatives
US7342003B2 (en) * 2001-10-25 2008-03-11 King Pharmaceuticals Research And Development, Inc. Synthesis of 2-aralkyloxyadenosines, 2-alkoxyadenosines, and their analogs
US7163928B2 (en) * 2003-02-03 2007-01-16 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
WO2005033121A2 (fr) * 2003-10-03 2005-04-14 King Pharmaceuticals Research & Development, Inc. Synthese de 2-aralkyloxyadenosines, 2-alkoxyadenosines, et leurs analogues
EP2021350B1 (fr) 2006-03-21 2016-12-21 Rheinische Friedrich-Wilhelms-Universität Bonn Agonistes du récepteur a2a phosphorylé
EP3082731B1 (fr) 2013-12-19 2018-07-04 The Procter and Gamble Company Façonnage de fibres de kératine utilisant un principe actif comprenant au moins deux groupes fonctionnels choisis entre -c(oh)- et -c(=o)oh
MX2017008204A (es) 2014-12-19 2017-10-06 Procter & Gamble Conformacion de las fibras de queratina mediante el uso de arabinosa y carbonato de etileno.
CN107106438A (zh) 2014-12-19 2017-08-29 宝洁公司 成形角蛋白纤维的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE768925A (fr) * 1970-06-30 1971-11-03 Takeda Chemical Industries Ltd Derives d'adenosine et procede de preparation
JPH0696534B2 (ja) * 1986-04-25 1994-11-30 ヘキストジヤパン株式会社 抗痴呆剤
US5017578A (en) * 1989-06-09 1991-05-21 Hoechst-Roussel Pharmaceuticals Inc. N-heteroaryl-purin-6-amines useful as analgesic and anticonvulsant agents
EP0423777A3 (en) * 1989-10-19 1991-09-25 G.D. Searle & Co. Method of treating gastrointestinal motility disorders
US5432164A (en) * 1991-10-24 1995-07-11 Novo Nordisk A/S C2,N6 -disubstituted adenosine derivatives

Also Published As

Publication number Publication date
FI941876A0 (fi) 1994-04-22
AU657374B2 (en) 1995-03-09
WO1993008206A1 (fr) 1993-04-29
EP0609375A1 (fr) 1994-08-10
ZA928222B (en) 1994-04-25
CA2121844A1 (fr) 1993-04-29
US5432164A (en) 1995-07-11
AU2916092A (en) 1993-05-21
NO941477D0 (no) 1994-04-22
US5578582A (en) 1996-11-26
JPH07500586A (ja) 1995-01-19
NZ244875A (en) 1995-04-27
IL103513A0 (en) 1993-03-15
IL103513A (en) 1996-09-12
FI941876A (fi) 1994-06-22
NO300461B1 (no) 1997-06-02

Similar Documents

Publication Publication Date Title
DE4290923T1 (fr)
DE4290412T1 (fr)
NO941477L (fr)
EP0525335A3 (fr)
DK0576484T3 (fr)
EP0520579A3 (fr)
DK0569364T3 (fr)
ECSM91576U (fr)
DE4291112T1 (fr)
EP0514050A3 (fr)
EP0520829A3 (fr)
CN3009795S (fr)
CN3009780S (fr)
CN3009754S (fr)
AU8454191A (fr)
AU8137891A (fr)
AU8114391A (fr)
EP0493840A3 (fr)
EP0495681A3 (fr)
EP0498366A3 (fr)
EP0498462A3 (fr)
EP0502808A3 (fr)
EP0503620A3 (fr)
EP0508666A3 (fr)
AU7938591A (fr)